| Identification | Back Directory | [Name]
Benzenesulfonamide, 3-cyano-4-[[3-[2-[[[2-(4-piperidinyl)ethyl]amino]methyl]-4-pyridinyl]-3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]oxy]-N-1,2,4-thiadiazol-5-yl- | [CAS]
1834610-73-9 | [Synonyms]
PF6456384
PF-6456384
PF 6456384
PF06456384
PF-06456384
PF 06456384
3-cyano-4-[2-[2-[(2-piperidin-4-ylethylamino)methyl]pyridin-4-yl]-4-[3-(trifluoromethyl)phenyl]phenoxy]-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide
Benzenesulfonamide, 3-cyano-4-[[3-[2-[[[2-(4-piperidinyl)ethyl]amino]methyl]-4-pyridinyl]-3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]oxy]-N-1,2,4-thiadiazol-5-yl- | [Molecular Formula]
C35H32F3N7O3S2 | [MOL File]
1834610-73-9.mol | [Molecular Weight]
719.8 |
| Hazard Information | Back Directory | [Description]
PF-06456384 is a highly potent and selective NaV1.7 inhibitor (IC50 NaV1.7 = 0.01 nM). PF-06456384 ultimately showed a lack of preclinical efficacy in a mouse formalin pain model and was not progressed further. PF-06456384 may be used to illustrate the potential to support further in vitro and in vivo evaluation of the translation of NaV1.7 inhibition to the treatment of pain. |
|
|